VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH CML 2022 | Final results of the BFORE trial: bosutinib vs imatinib in CP-CML

Michael Deininger, MD, PhD, The Medical College of Wisconsin, Milwaukee, WI, gives an overview of the final results of the BFORE trial (NCT02130557) which compared imatinib versus bosutinib in patients with chronic phase chronic myeloid leukemia (CP-CML). Overall, the BFORE trial demonstrated the superiority of bosutinib over imatinib in terms of depth of response and toxicity, but did not show a difference in overall survival (OS). This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Novartis, BMS, Incyte, Takeda, Blueprint, Cogent, CTI.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter